Pfizer’s stock has dropped due to the end of a COVID-related revenue surge, but its dividend payment remains secure. The company has consistently paid out dividends and increased them for 16 years. Despite a revenue decline, Pfizer is expecting to launch at least eight new blockbuster drugs by 2030, adding $20-25 billion in revenue.

While Pfizer’s stock has suffered, the company has plans for growth through new blockbuster drugs. The market may have priced in the revenue decline too aggressively. With a high dividend yield, risks are already factored in. The Motley Fool Stock Advisor team identified 10 stocks they believe will outperform Pfizer in the future, suggesting potential for significant returns.

Investors are urged to consider the potential for growth in other stocks besides Pfizer. Companies like Netflix and Nvidia have seen substantial returns after being recommended by The Motley Fool Stock Advisor team. Past recommendations have yielded impressive results, with the potential for significant returns on future picks.

Read more at Yahoo Finance: This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone’s Sleeping)